

11<sup>th</sup> March 2025

Polar Capital Global Healthcare Trust plc (the "Company")

Top Ten Equity Holdings and Sector and Geographic Exposure as at 28<sup>th</sup> February 2025

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 28th February 2025 the top ten equity holdings and the sector and geographic breakdown were as follows:

<b>Top 10 Holdings</b>	<b>%</b>
Eli Lilly & Co	9.4%
UnitedHealth Group	7.6%
Novo Nordisk A/S	6.2%
Abbott Laboratories	5.3%
UCB	3.8%
Roche	3.7%
Intuitive Surgical	3.7%
Sanofi	3.6%
DexCom	3.5%
Fresenius SE & Co KGaA	3.2%
<b>Total</b>	<b>49.9%</b>

<b>Sector Exposure</b>	<b>%</b>
Pharmaceuticals	31.4%
Healthcare Equipment	25.4%
Biotechnology	13.8%
Managed Healthcare	7.6%
Life Sciences Tools & Services	5.4%
Healthcare Supplies	4.4%
Healthcare Distributors	3.9%
Healthcare Services	3.2%
Metal, Glass & Plastic Containers	2.7%
Healthcare Technology	1.3%
Healthcare Facilities	0.7%
Cash	0.3%
<b>Total</b>	<b>100.0%</b>

<b>Geographic Exposure</b>	<b>%</b>
United States	49.0%
Denmark	11.4%
Switzerland	10.8%
France	6.2%
Japan	5.2%
Belgium	3.8%
Germany	3.2%
Netherlands	3.0%
Sweden	2.1%
United Kingdom	2.0%
Italy	2.0%
Ireland	1.0%
Cash	0.3%
<b>Total</b>	<b>100.0%</b>

The monthly factsheet will usually be available on the Company's website on the 10<sup>th</sup> working day after the month end and includes a commentary by the investment manager. [www.Polarcapitalhealthcaretrust.com](http://www.Polarcapitalhealthcaretrust.com)

**Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PFUGPUWPWUPAGQG